ABSTRACT
The dominant player behind the Trade-Related Intellectual Property (TRIPs) agreement, as regards patents, was a handful of American pharmaceutical transnational corporations (‘big pharma’). Given that TRIPs was exceptionally controversial, how was US big pharma uniquely enabled to command the entire trade diplomatic machinery of the US and, through that, enact global law in its favour? This paper explores one crucial factor in the enacting of TRIPs, namely the prior pursuit of domestic US patent reform, from which a highly integrated and powerful single-issue political coalition between US big pharma, the new biotechnology sector and academic life science departments was formed. This created the political context in the US in which patent issues, particularly those affecting the pharmaceuticals industry, came to be considered matters of state. But explaining both the success of this patent coalition and the subsequent success of the US-led international demands for TRIPs in turn demands appeal to analysis of the structure of the global economy and its transformation to one of neoliberal financialisation, from a watershed of 1980. The paper explores how the critical histories of each of the three sectors of the patent coalition are illuminated by analysis in the context of this structural change and the underlying connections between apparently disparate issues it reveals.
Notes
5 Though TNCs are now beginning to exploit the possibilities of moving R&D to less developed countries with a relevant knowledge base (CitationReddy, 2000).
8 See e.g. Angell (Citation2005: xxiv), who notes the importance of another form of monopoly rights provided in the US to address this problem, namely, the exclusive marketing rights from the Food and Drug Administration (FDA).
11 In fact, such patenting was not completely prohibited, but was allowed only after a laborious administrative process in which special approval was granted to patent (CitationSlaughter and Rhoades, 2002: 85).
12 On fears of Reagan's cuts, see Kenney (Citation1986: 28).
13 The percentage of basic research R&D funding going to the life sciences rose in the 1970s from 36% to 44% – in parallel to the increase in the percentage funded by the NIH, from 36.7% in 1971 to 47% in 1981 (CitationMowery et al., 2004, using National Science Board data) – while that going to physics fell from 18% to 14% (CitationMirowski and Sent, 2002: 24). ‘NIH’ is the National Institutes of Health, the primary federal funding agency for the life sciences in the US.
15 For example, CitationMowery et al. (2001), esteemed economists of innovation and no political radicals, argue that these reforms were based on ‘a belief by policymakers (based on little or no evidence) that stronger protection for the results of publicly funded R&D would accelerate their commercialization’. See also CitationEisenberg (1996).
20 Data from Fortune 500, author's calculation.
21 For comparison, in 2001, 35% of PhRMA revenues were spent on ‘marketing & administration’, of which roughly three quarters was marketing (CitationAngell, 2005: 120, using PhRMA data), hence 27%. Conversely, R&D represented 16.7% of total revenues that year (CitationPhRMA, 2005).
22 Examples of minor modifications remarketed under new brand names include Clarinex to Claritin, Prozac to Sarafem, Prilosec to Nexium (CitationAngell, 2005: 76 et seq).
24 Bud (Citation1998: 14) pins down the start of this financial frenzy exactly to June 1979 when Nelson Schneider of investment house E F Hutton heard about Genentech's production of human insulin, became interested and reported biotech to investors as a major technological breakthrough.
25 For a full discussion of the case and the effect of the judgment, see Krimsky (Citation2003: 62 et seq).
27 Jaffe (Citation2000: 543) and Author's calculations using USPTO data. Note also that this is just for one class of biotechnology patents.
28 Rai and Eisenberg (Citation2003: 300) report that in 2000 the top five universities grossed nearly one-half of total licensing revenues, while CitationThursby and Thursby (2003) note that in the same year only 43% of licenses earned royalties at all, and only 0.56% earned over $1 million.
29 See also Mowery et al. (Citation2001: 104) and Owen-Smith and Powell (Citation2003: 1697), who note that biotech patents were 49.5% of all university patents.
30 Federal funding of total US R&D fell below the 50% mark in 1979 and continued to decline to a low of 25% in 2000, while funding from private industry has taken the opposite path: see CitationNSF (2006b).
31 For instance, Angell (Citation2005: 71) notes that the universities are just as resistant as big pharma to rigorous enforcement of a clause in the Bayh–Dole Act that demands ‘reasonable terms’ for the contracts resulting from such patents, as this may offend their big pharma sponsors.
32 At approximately 50% of investment in Europe in 1999 as opposed to ‘basic’ at 12%, cell factory and plant biotech each 9% and animal biotech 8%: Senker (Citation2000: 57). Dutfield (Citation2003: 146) reports 60% of US and EU biotech firms produce health-related products.
35 CitationSell (2003) discusses a similar phenomenon as regards US trade legislation at the time, which during the TRIPs negotiations continually upgraded the privileged position US trade policy provided big pharma. Kenney (Citation1986: 242) also notes the irreducible role of the state in the development of biotech. See also the discussion of CitationMirowski and Sent (2008) regarding a tripartite analysis of relations between academia, industry and government.
36 This is not to deny the importance of EU or Japanese pharmaceutical companies regarding the actual TRIPs negotiations, and their own respective domestic political agency. Nevertheless, the TRIPs agreement was overwhelmingly an American initiative (CitationSell, 2003) and I focus on the US aspect for lack of space. For an excellent comparison of the US, UK and Germany regarding biotech and the commercialization of the university, see CitationJasanoff (2005).
Maskus
,
K.
2000
.
Intellectual Property Rights in the Global Economy
,
Washington, DC
:
Institute for International Economics
.
Sell
,
S.
2003
.
Private Power, Public Law: The Globalization of Intellectual Property Rights
,
Cambridge
:
Cambridge University Press
.
Drahos
,
P.
and
Braithwaite
,
J.
2002
.
Information Feudalism: Who Owns the Knowledge Economy?
,
London
:
Earthscan
.
Dutfield
,
G.
2003
.
Intellectual Property Rights and the Life Science Industries: A 20th Century History
,
Aldershot
:
Ashgate
.
Matthews
,
D.
2002
.
Globalising Intellectual Property Rights: The TRIPs Agreement
,
London
:
Routledge
.
May
,
C.
2000
.
A Global Political Economy of Intellectual Property Rights
,
London and New York
:
Routledge
.
Richards
,
D.
2004
.
Intellectual Property Rights and Global Capitalism–The Political Economy of the TRIPS Agreement
,
Armonk, NY and London
:
M. E. Sharpe
.
Reddy
,
P.
2000
.
The Globalization of Corporate R&D: Implications for Host Countries
,
London
:
Routledge
.
Hymer
,
S.
1975
.
“
‘The Multinational Corporation and the Law of Uneven Development’
”
. In
International Firms and Modern Imperialism – Selected Readings
,
Edited by:
Radice
,
H.
Harmondsworth
:
Penguin Books
.
Hymer
,
S.
1979
.
The Multinational Corporation: A Radical Approach: Papers by Stephen Herbert Hymer
,
Edited by:
Cohen
,
Robert B.
,
Felton
,
Nadine
,
Nkosi
,
Morley
and
van Liere
,
Jaap
.
Cambridge
:
Cambridge University Press
.
Castells
,
M.
1993
.
“
‘The Informational Economy and the New International Division of Labor’
”
. In
The New Global Economy in the Information Age: Reflections on our Changing World
,
Edited by:
Carnoy
,
M.
University Park, PA
:
Pennsylvania State University Press
.
Castells
,
M.
1996
.
The Rise of the Network Society
,
Malden, MA and Oxford
:
Blackwell
.
Castells
,
M.
1997
.
The Power of Identity
,
Malden, MA and Oxford
:
Blackwell
.
Castells
,
M.
1998
.
End of Millennium
,
Malden, MA and Oxford
:
Blackwell
.
Drori
,
G.
2003
.
Science in the Modern World Polity: Institutionalization and Globalization
,
Stanford
:
Stanford University Press
.
Carnoy
,
M.
1993a
.
“
‘Introduction’
”
. In
The New Global Economy in the Information Age: Reflections on our Changing World
,
Edited by:
Carnoy
,
M.
University Park, PA
:
Pennsylvania State University Press
.
Carnoy
,
M.
1993b
.
“
‘Multinationals in a Changing World Economy: Whither the Nation-State?’
”
. In
The New Global Economy in the Information Age: Reflections on our Changing World
,
Edited by:
Carnoy
,
M.
University Park, PA
:
Pennsylvania State University Press
.
Drahos
,
P.
and
Braithwaite
,
J.
2002
.
Information Feudalism: Who Owns the Knowledge Economy?
,
London
:
Earthscan
.
Reddy
,
P.
2000
.
The Globalization of Corporate R&D: Implications for Host Countries
,
London
:
Routledge
.
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Arrighi
,
G.
2003
.
‘The Social and Political Economy of Global Turbulence’
.
New Left Review
,
20
:
5
–
71
.
Arrighi
,
G.
2005a
.
‘Hegemony Unravelling – 1’
.
New Left Review
,
32
:
23
–
82
.
Arrighi
,
G.
2005b
.
‘Hegemony Unravelling – 2’
.
New Left Review
,
33
:
83
–
116
.
Public Citizen
.
2003b
.
‘2002 Drug Industry Profits: Hefty Pharmaceutical Company Margins Dwarf Other Industries’
www.citizen.org
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Public Citizen
.
2001b
.
‘Rx R&D Myths: The Case Against the Drug Industry's R&D Scare Card’
www.citizen.org
Taylor
,
C.
and
Silberstom
,
Z.
1973
.
The Economic Impact of the Patent System
,
Cambridge
:
Cambridge University Press
.
MacDonald
,
S.
2002
.
“
‘Exploring the Hidden Costs of Patents’
”
. In
Global Intellectual Property Rights: Knowledge, Access and Development
,
Edited by:
Drahos
,
P.
and
Mayne
,
R.
Basingstoke
:
Palgrave Macmillan
.
Cohen
,
W.
,
Nelson
,
R.
and
Walsh
,
J. P.
2002
.
‘Links and Impacts: The Influence of Public Research on Industrial R&D’
.
Management Science
,
48
(
1
)
:
1
–
23
.
Cohen
,
W.
and
Merrill
,
S.
2003
.
“
‘Introduction’
”
. In
Patents in the Knowledge-Based Economy
,
Edited by:
Cohen
,
W.
and
Merrill
,
S.
Washington, DC
:
National Academy Press
.
Levin
,
R.
,
Klevorick
,
A.
,
Nelson
,
R.
and
Winter
,
S.
1987
.
‘Appropriating the Returns from Industrial Research and Development’
.
Brookings Papers on Economic Activity
,
3
:
783
–
831
.
Mansfield
,
E.
1986
.
‘Patents and Innovation: An Empirical Study’
.
Management Science
,
32
(
2
)
:
173
–
81
.
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Sell
,
S.
2003
.
Private Power, Public Law: The Globalization of Intellectual Property Rights
,
Cambridge
:
Cambridge University Press
.
Gallini
,
N. T.
2002
.
‘The Economics of Patents: Lessons from Recent U. S. Patent Reform’
.
The Journal of Economic Perspectives
,
16
(
2
)
:
131
–
54
.
Orsenigo
,
L.
1989
.
The Emergence of Biotechnology – Institutions and Markets in Industrial Innovation
,
London
:
Pinter
.
Kenney
,
M.
1986
.
Biotechnology: The University–Industrial Complex
,
London and New Haven, CT
:
Yale University Press
.
Slaughter
,
S.
and
Rhoades
,
G.
2002
.
“
‘The Emergence of a Competitiveness Research and Development Policy Coalition and the Commercialization of Academic Science and Technology’
”
. In
Science Bought and Sold
,
Edited by:
Mirowski
,
P.
and
Sent
,
E.-M.
Chicago
:
University of Chicago Press
.
Kenney
,
M.
1986
.
Biotechnology: The University–Industrial Complex
,
London and New Haven, CT
:
Yale University Press
.
Mowery
,
D.
,
Nelson
,
R.
,
Sampat
,
B.
and
Ziedonis
,
A.
2004
.
Ivory Tower and Industrial Innovation
,
Stanford
:
Stanford University Press
.
Mirowski
,
P.
and
Sent
,
E.-M.
, eds.
2002
.
Science Bought and Sold
,
Chicago
:
University of Chicago Press
.
Calvert
,
J.
2004
.
‘The Idea of “Basic Research” in Language and Practice’
.
Minerva
,
45
:
251
–
68
.
Mowery
,
D.
,
Nelson
,
R.
,
Sampat
,
B.
and
Ziedonis
,
A.
2001
.
‘The Growth of Patenting and Licensing by U. S. Universities: An Assessment of the Effects of the Bayh-Dole act of 1980’
.
Research Policy
,
30
:
99
–
119
.
Eisenberg
,
R.
1996
.
‘Public Research and Private Development: Patents and Technology Transfer in Government-Sponsored Research’
.
Virginia Law Review
,
82
:
1663
–
727
.
Orsenigo
,
L.
1989
.
The Emergence of Biotechnology – Institutions and Markets in Industrial Innovation
,
London
:
Pinter
.
Mazzoleni
,
R.
and
Nelson
,
R.
1998
.
‘Economic Theories about the Benefits and Costs of Patents’
.
Journal of Economic Issues
,
32
(
4
)
:
1031
–
52
.
Nelson
,
R.
2001
.
‘Observations on the Post-Bayh–Dole Rise of Patenting at American Universities’
.
Journal of Technology Transfer
,
26
:
13
–
19
.
Heller
,
M.
and
Eisenberg
,
R.
1998
.
‘Can Patents Deter Innovation? The Anti-Commons in Biomedical Research’
.
Science
,
280
:
698
–
701
.
Cohen
,
W.
,
Nelson
,
R.
and
Walsh
,
J. P.
2002
.
‘Links and Impacts: The Influence of Public Research on Industrial R&D’
.
Management Science
,
48
(
1
)
:
1
–
23
.
Klevorick
,
A.
,
Levin
,
R.
,
Nelson
,
R.
and
Winter
,
S.
1995
.
‘On the Sources and Significance of Interindustry Differences in Technological Opportunities’
.
Research Policy
,
24
(
2
)
:
185
–
205
.
Levin
,
R.
,
Klevorick
,
A.
,
Nelson
,
R.
and
Winter
,
S.
1987
.
‘Appropriating the Returns from Industrial Research and Development’
.
Brookings Papers on Economic Activity
,
3
:
783
–
831
.
Rosenberg
,
N.
and
Nelson
,
R.
1994
.
‘American Universities and Technical Advance in Industry’
.
Research Policy
,
23
:
323
–
48
.
Pharmaceutical Research and Manufacturers of America (PhRMA)
.
2005
.
Pharmaceutical Industry Profile 2005
,
Washington, DC
:
PhRMA
.
Arrighi
,
G.
2003
.
‘The Social and Political Economy of Global Turbulence’
.
New Left Review
,
20
:
5
–
71
.
Arrighi
,
G.
2005a
.
‘Hegemony Unravelling – 1’
.
New Left Review
,
32
:
23
–
82
.
Arrighi
,
G.
2005b
.
‘Hegemony Unravelling – 2’
.
New Left Review
,
33
:
83
–
116
.
Arrighi
,
G.
2005a
.
‘Hegemony Unravelling – 1’
.
New Left Review
,
32
:
23
–
82
.
Arrighi
,
G.
2005b
.
‘Hegemony Unravelling – 2’
.
New Left Review
,
33
:
83
–
116
.
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Pharmaceutical Research and Manufacturers of America (PhRMA)
.
2005
.
Pharmaceutical Industry Profile 2005
,
Washington, DC
:
PhRMA
.
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Angell
,
M.
2006
.
‘Your Dangerous Drugstore’
.
New York Review of Books
,
53
(
10
)
8 June
Abramson
,
J.
2004
.
Overdosed America: The Broken Promise of American Medicine
,
New York
:
HarperCollins
.
Avorn
,
J.
2004
.
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs
,
New York
:
Knopf
.
Goozner
,
M.
2004
.
The $800 Million Pill: The Truth Behind the Cost of New Drugs
,
Berkeley
:
University of California Press
.
Kassirer
,
J. P.
2004
.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
,
Oxford
:
Oxford University Press
.
Moynihan
,
R.
and
Cassels
,
A.
2005
.
Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients
,
New York
:
Nation Books
.
Olfman
,
S.
, ed.
2006
.
No Child Left Different
,
Westport, CT
:
Praeger
.
Bud
,
R.
1998
.
“
‘Molecular Biology and the Long-Term History of Biotechnology’
”
. In
Private Science: Biotechnology and the Rise of the Molecular Sciences
,
Edited by:
Thackray
,
A.
Philadelphia
:
University of Pennsylvania Press
.
Krimsky
,
S.
2003
.
Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research?
,
Lanham
:
Rowman & Littlefield
.
Mowery
,
D.
,
Nelson
,
R.
,
Sampat
,
B.
and
Ziedonis
,
A.
2001
.
‘The Growth of Patenting and Licensing by U. S. Universities: An Assessment of the Effects of the Bayh-Dole act of 1980’
.
Research Policy
,
30
:
99
–
119
.
Mowery
,
D.
,
Nelson
,
R.
,
Sampat
,
B.
and
Ziedonis
,
A.
2004
.
Ivory Tower and Industrial Innovation
,
Stanford
:
Stanford University Press
.
Kortum
,
S.
and
Lerner
,
J.
1999
.
‘What is Behind the Recent Surge in Patenting?’
.
Research Policy
,
28
:
1
–
22
.
Jaffe
,
A.
2000
.
‘The U. S. Patent System in Transition: Policy Innovation and the Innovation Process’
.
Research Policy
,
29
:
531
–
57
.
Rai
,
A.
and
Eisenberg
,
R.
2003
.
‘Bayh–Dole Reform and the Progress of Biomedicine’
.
Law and Contemporary Problems
,
66
:
289
–
314
.
Thursby
,
J.
and
Thursby
,
M.
2003
.
‘University Licensing and the Bayh–Dole Act’
.
Science
,
301
:
1052
Mowery
,
D.
,
Nelson
,
R.
,
Sampat
,
B.
and
Ziedonis
,
A.
2001
.
‘The Growth of Patenting and Licensing by U. S. Universities: An Assessment of the Effects of the Bayh-Dole act of 1980’
.
Research Policy
,
30
:
99
–
119
.
Owen-Smith
,
J.
and
Powell
,
W.
2003
.
‘The Expanding Role of University Patenting in the Life Sciences: Assessing the Importance of Experience and Connectivity’
.
Research Policy
,
32
:
1695
–
711
.
Angell
,
M.
2005
.
The Truth about the Drug Companies: How They Deceive Us and What to Do about it
,
New York
:
Random House Trade Paperbacks
.
Senker
,
J.
2000
.
“
‘Biotechnology: Scientific Progress and Social Progress’
”
. In
Economics and Social Dynamics of Biotechnology
,
Edited by:
de la Mothe
,
J.
and
Niosi
,
J.
London
:
Kluwer Academic
.
Dutfield
,
G.
2003
.
Intellectual Property Rights and the Life Science Industries: A 20th Century History
,
Aldershot
:
Ashgate
.
Blackburn
,
S.
2006
.
‘Finance's Fourth Dimension’
.
New Left Review
,
39
:
39
–
72
.
Harvey
,
D.
1982
.
Limits to Capital
,
Oxford
:
Basil Blackwell
.
Harvey
,
D.
2003
.
The New Imperialism
,
Oxford
:
Oxford University Press
.
Bieler
,
A.
and
Morton
,
A.
2004
.
‘A Critical Theory Route to Hegemony, World Order and Historical Change: Neo-Gramscian Perspectives in International Relations’
.
Capital & Class
,
82
:
85
–
113
.
Cox
,
R.
1987
.
Production, Power, and World Order
,
New York and Guildford
:
Columbia University Press
.
Cox
,
R.
and
Sinclair
,
T.
1996
.
Approaches to World Order
,
Cambridge
:
Cambridge University Press
.
Gill
,
S.
, ed.
1993
.
Gramsci, Historical Materialism and International Relations
,
Cambridge
:
Cambridge University Press
.
Gramsci
,
A.
1971
.
Selections from the Prison Notebooks
,
Edited by:
Hoare
,
Q.
and
Nowell Smith
,
G.
London
:
Lawrence Wishart
.
Harvey
,
D.
2003
.
The New Imperialism
,
Oxford
:
Oxford University Press
.
Jessop
,
B.
1997
.
‘Capitalism and its Future: Remarks on Regulation, Government and Governance’
.
Review of International Political Economy
,
4
(
3
)
:
561
–
81
.
Jessop
,
B.
and
Sum
,
N.-L.
2006
.
“
‘Towards a Cultural International Political Economy: Post-Structuralism and the Italian School’
”
. In
International Political Economy and Poststructural Politics
,
Edited by:
de Goede
,
M.
Basingstoke
:
Palgrave Macmillan
.
Sell
,
S.
2003
.
Private Power, Public Law: The Globalization of Intellectual Property Rights
,
Cambridge
:
Cambridge University Press
.
Kenney
,
M.
1986
.
Biotechnology: The University–Industrial Complex
,
London and New Haven, CT
:
Yale University Press
.
Mirowski
,
P.
and
Sent
,
E.-M.
2008
.
“
‘The Commercialization of Science and the Response of STS’
”
. In
New Handbook of STS
,
Edited by:
Hackett
,
E.
,
Wacjman
,
J.
,
Amsterdamska
,
O.
and
Lynch
,
M.
Cambridge, MA
:
MIT Press
.
Sell
,
S.
2003
.
Private Power, Public Law: The Globalization of Intellectual Property Rights
,
Cambridge
:
Cambridge University Press
.
Jasanoff
,
S.
2005
.
Designs on Nature: Science and Democracy in Europe and the United States
,
Princeton, NJ and Oxford
:
Princeton University Press
.